ALX Oncology, Inc.

Sutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c

A little over two months into 2025 and two Chinese drug makers have reaped the successes of moving their first-in-class pipeline innovations onto the domestic market, while two others have encountered

Phase II data for ALX Oncology’s evorpacept in gastric cancer raises the possibility that the company can succeed in an immunotherapy field that even some large drug companies have exited due to resul

For inclusion in 2023’s list , an asset had to be wholly owned, outside of clinical trial collaborations or small, regional tie-ups, and its developer unlikely to want to launch alone. The table was